ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023Interim data from...

Related Keywords

San Diego ,California ,United States ,France ,San Diego Convention Center ,Volker Kunzmann ,Institut Paoli Calmettes ,Gretchen Schweitzer ,Paul Frohna ,Francois Xavier Danlos ,Katrien Lemmens ,Maelle Mairesse ,Patrick Brune ,Emmanuel Valentin ,Martin Wermke ,Marseille Immunopole ,Society For Immunotherapy Of Cancer ,University Of London ,Institute Of Cancer Research ,Trophic Communications ,Marseille University ,Regius Professor Of Cancer Research ,Imcheck Presented Updated Positive Data ,Imcheck Therapeutics ,Low Dose ,Robust Anti Tumor Immune Activation ,Advanced Cancer Patients ,Regius Professor ,Cancer Research ,Chief Executive Officer ,Clinical Trials ,Johann De Bono ,Aude De Gassart ,Marina Iche ,Daniel Olive ,Friday November ,Ground Level ,Diego Convention ,Aix Marseille University ,